Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

Julien Taieb,Yves Rinaldi,Anne-Laure Pointet,Emilie Barbier,Faiza Khemissa,Alain Gratet,Laurent Miglianico,Hortense Laharie Mineur,Karine Bouhier-Leporrier,FranÃ§ois Ghiringhelli,Anne Thirot-Bidault,Patrick Texereau,Romain Coriat,Eric Terrebonne,Marie-Claude Gouttebel,David Malka,Côme Lepage,Jean-Baptiste Bachet

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

2018

Julien Taieb
Yves Rinaldi
Anne-Laure Pointet
Emilie Barbier
Faiza Khemissa
Alain Gratet
Laurent Miglianico
Hortense Laharie Mineur
Karine Bouhier-Leporrier
FranÃ§ois Ghiringhelli
Anne Thirot-Bidault
Patrick Texereau
Romain Coriat
Eric Terrebonne
Marie-Claude Gouttebel
David Malka
Côme Lepage
Jean-Baptiste Bachet

4107Background: Chemotherapy is effective in mPDAC but new approaches are still needed to improve patients (pts) survival and quality of life. We have previously published successful results of a s...

Keywords:

Nab-paclitaxel
FOLFIRI
Oncology
Phases of clinical research
Pathology
Gemcitabine
Medicine
Adenocarcinoma
Irinotecan
Internal medicine
Chemotherapy
pancreatic ductal adenocarcinoma
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations